Esquemas terapéuticos de primera elección para el cáncer de mama en la unidad de mezclas oncológicas del Instituto Regional de Enfermedades Neoplásicas norte – IREN - durante los meses de enero - diciembre del 2012

• Autor: Paucar Asmat, Luis Edgardo
• Formato: tesis de grado
• Fecha de Publicación: 2013
• Institución: Universidad Nacional de Trujillo
• Repositorio: UNITRU-Tesis
• Lenguaje: español
• OAI Identifier: oai:dspace.unitru.edu.pe:20.500.14414/3936
• Enlace del recurso: https://hdl.handle.net/20.500.14414/3936
• Nivel de acceso: acceso abierto
• Materia: Esquema de tratamiento en el cáncer de mama. principio de pareto.

In the present work is to determine the therapeutic regimens of choice for breast cancer oncology unit mixes the Regional Institute of Neoplastic Diseases "Dr. Luis Pinillos Ganoza "with the objective of determining therapeutic regimens of choice for breast cancer oncology unit mixtures (SMO) of the Regional Institute of Neoplastic Diseases, identify patterns of cancer treatment of choice for breast cancer service Regional chemotherapy of Neoplastic Diseases Institute North, determine the frequency of use quarterly treatment regimens, as Pareto's law, in breast cancer chemotherapy service, classify most widely used regimens in chemotherapy breast Cancer chemotherapy service. To which we conducted a cross-sectional study, which included retrospective inpatients affiliated comprehensive health system during the period January to December 2012. We found that paclitaxel scheme, was the first treatment regimen used in the IREN-north during the first quarter (42.71%), second quarter (44.88%), third quarter (52.93%), fourth quarter (57.51%). the second treatment regimen used was doxorubicin - cyclophosphamide in IREN-north during the first quarter (28.47%), second quarter (30.17%), third quarter (27.80%), fourth quarter (26.06%), we could also observe that Paclitaxel scheme, was the most widely used since the administration of this therapeutic regimen is weekly while the AC scheme is administered every 21 days and the AC scheme is the scheme of choice for breast cancer.